Autifony Therapeutics

Autifony Therapeutics company information, Employees & Contact Information

Autifony Therapeutics Limited (“Autifony”) is a clinical stage biotechnology company dedicated to developing new medicines to treat rare genetic CNS disorders by deploying its pioneering ion channel drug discovery platform.

Company Details

Employees
30
Founded
-
Address
Stevenage
Email
in****@****ony.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
jobs.
HQ
Stevenage
Looking for a particular Autifony Therapeutics employee's phone or email?

Autifony Therapeutics Questions

News

Jazz locks arms with GSK spinout Autifony, putting up $771M to form neuroscience discovery pact - Fierce Biotech

Jazz locks arms with GSK spinout Autifony, putting up $771M to form neuroscience discovery pact Fierce Biotech

Autifony and Jazz enter $770.5m drug development deal - Pharmaceutical Technology

Autifony and Jazz enter $770.5m drug development deal Pharmaceutical Technology

Jazz Inks $770M Deal with GSK Spinout Autifony, Nabs Two Neuro Assets - BioSpace

Jazz Inks $770M Deal with GSK Spinout Autifony, Nabs Two Neuro Assets BioSpace

Boehringer Ingelheim inks CNS deal with Autifony - BioPharma Dive

Boehringer Ingelheim inks CNS deal with Autifony BioPharma Dive

Autifony, Jazz Partner on Ion Channel Targets for Neurological Disorders - Contract Pharma

Autifony, Jazz Partner on Ion Channel Targets for Neurological Disorders Contract Pharma

Autifony swings $770.5m deal with Jazz for CNS drugs - pharmaphorum

Autifony swings $770.5m deal with Jazz for CNS drugs pharmaphorum

GSK takes minority stake in new spin out Autifony Therapeutics - GSK

GSK takes minority stake in new spin out Autifony Therapeutics GSK

Voltage-gated potassium channels as a potential therapeutic target for the treatment of neurological and psychiatric disorders - Frontiers

Voltage-gated potassium channels as a potential therapeutic target for the treatment of neurological and psychiatric disorders Frontiers

Boehringer renews collaboration with Autifony - The Pharma Letter

Boehringer renews collaboration with Autifony The Pharma Letter

Autifony agrees Jazz Pharmaceuticals deal worth up to $770.5m - Insider Media Ltd

Autifony agrees Jazz Pharmaceuticals deal worth up to $770.5m Insider Media Ltd

[Withdrawn] Schizophrenia treatment: funding enables next-stage trials - GOV.UK

[Withdrawn] Schizophrenia treatment: funding enables next-stage trials GOV.UK

Top Autifony Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant